hero-purple

About

With founders who are global leaders in the structural biology of 14-3-3 proteins and their role in a wide range of protein-protein interactions, our team is developing a new class of medicines that can modulate previously undruggable targets and influence currently accessible ones in new ways. These small molecule stabilizers of 14-3-3:client complexes have the potential to address serious unmet needs in important therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.

Our company is committed to aggressively expanding the boundaries of medicine through treatments that modulate some of the most challenging and potentially impactful targets identified across the proteome, with the goal of treating diseases that currently lack a cure and helping patients live longer and healthier lives.

Ambagon-Photo-SClarke1162Edit-Web-sized

Scott Clarke

Chief Executive Officer

Ambagon-Photo-COttmann1324Edit-Web-sized

Christian Ottmann, Ph.D.

Co-Founder & Chief Technology Officer

Ambagon-Photo-NPryor1759Edit-Web-sized

Nancy Pryer, Ph.D.

Chief Scientific Officer

Ambagon-Photo-SRichards1537Edit-Web-resized

Steven Richards, Ph.D.

Vice President, Chemistry

Michelle Arkin, Ph.D.

Co-Founder, Ambagon Therapeutics, Professor and Chair, Pharmaceutical Chemistry UCSF

Roel Bulthuis

Managing Partner, Inkef Capital

Margarita Chavez

Managing Partner, AbbVie Ventures

Scott Clarke

Chief Executive Officer, Ambagon Therapeutics

Peter Dudek, Ph.D.

President & Managing Partner, MRL Ventures Fund

Melissa McCracken, Ph.D.

Partner, Nextech Invest

Janwillem Naesens

Managing Partner, DROIA Ventures

Adam Rosenberg

Chair, Venture Partner, RA Capital

Michelle Arkin, Ph.D.

University of California, San Francisco

Alan Ashworth, Ph.D., FRS

University of California, San Francisco

Carolyn Bertozzi, Ph.D.

Stanford University

Gideon Bollag, Ph.D.

Opna-IO

Luc Brunsveld, Ph.D.

Co-Founder, Scientific Advisor

Steve Davidsen, Ph.D.

AbbVie

Geraldine Harriman, Ph.D.

HotSpot Therapeutics

Ali Tavassoli, Ph.D.

University of Southampton

0022_Ambagon-Photo-MArkinEdit

Michelle Arkin, Ph.D.

Co-founder

0021_Ambagon-Photo-ZZhang4898Edit

Zhen Zhang, Ph.D.

Director, Cancer Biology

0000_Ambagon-Photo-GMiley1509Edit

Galen Miley, Ph.D.

Scientist, Chemistry

0005_Ambagon-Photo-LStevers1248Edit

Loes Stevers, Ph.D.

Senior Scientist, Biochemistry

0003_Ambagon-Photo-LDemmers1406Edit

Laura Demmers, Ph.D.

Scientist, Proteomics

0002_Ambagon-Photo-ESijbesma1294Edit

Eline Sijbesma, Ph.D.

Scientist, Biochemistry

0016_Ambagon-Photo-MHowarth4972Edit

Michelle Howarth, Ph.D.

Senior Scientist, Cancer Biology

0015_Ambagon-Photo-WGoodheart4925Edit-copy

William Goodheart

Associate Scientist, Cancer Biology

0011_Ambagon-Photo-LBrunsveld1806Edit

Luc Brunsveld, Ph.D.

Co-founder

0013_Ambagon-Photo-RdeVries1648Edit

Rens de Vries, Ph.D.

Scientist, Structural Biology

Investors

RAcapital logo
mrl ventures fund logo
mission bay capital logo
inkef capital logo
droia ventures logo
abbvie logo